CCR5 and gastric cancer: The second line of evidence that CCR5 inhibition may augment immune checkpoint inhibitors or cellular immunotherapy (ICI) responses includes animal model studies of gastric cancer in which an anti-CCR5 antibody decreased the number of tumor M-MDSCs and G-MDSCs.